Ausgabe 2/2021
Inhalt (10 Artikel)
Leading Article
Imeglimin: Current Development and Future Potential in Type 2 Diabetes
Chigoziri Konkwo, Rachel J. Perry
Open Access
Leading Article
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
Nityam Rathi, Taylor Ryan McFarland, Roberto Nussenzveig, Neeraj Agarwal, Umang Swami
Open Access
Review Article
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
Jerold Chun, Gavin Giovannoni, Samuel F. Hunter
Review Article
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia
George G. Zhanel, Christina Deng, Sheryl Zelenitsky, Courtney K. Lawrence, Heather J. Adam, Alyssa Golden, Liam Berry, Frank Schweizer, Michael A. Zhanel, Neal Irfan, Denice Bay, Philippe Lagacé-Wiens, Andrew Walkty, Lionel Mandell, Joseph P. Lynch III, James A. Karlowsky
Open Access
Original Research Article
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Kay Noonan, Yiyun Tang, Malaika Pastel, Keith D. Wilner, Yi-Long Wu
Adis Drug Evaluation
Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC
Sheridan M. Hoy